Aster Capital Management (Difc) LTD Supernus Pharmaceuticals, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $540 Billion
- Q1 2025
A detailed history of Aster Capital Management (Difc) LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 1,914 shares of SUPN stock, worth $61,688. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,914
Previous 345
454.78%
Holding current value
$61,688
Previous $12.5 Million
391.89%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$335 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$199 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$167 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$93.6 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$87 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...